The Global Antibiotic Research and Development Partnership (GARDP) has launched a stage-three trial of zoliflodacin, a potential new antibiotic to treat gonorrhoea, in South Africa as well as the United States, the Netherlands and Thailand.
The World Health Organisation started the GARDP in 2016. It is a non-profit organisation focused on developing new treatments for infections which have become resistant to available treatments. It says its mission is to produce new medicines which are accessible and affordable to all who need them.
Zoliflodacin is being trialled at three sites in South Africa – the Wits Reproductive Health and HIV Institute based at the Hillbrow Health Precinct in Johannesburg, and two South African Medical Research Council sites at Tongaat and Botha’s Hill in KwaZulu-Natal.
United-states
Thailand
Netherlands
Hillbrow
Gauteng
South-africa
Tongaat
Kwazulu-natal
Johannesburg
Kwazulu
Eastern-cape
Natal
A once-monthly pill intake has shown promising results in the quest to prevent HIV infections, scientists have said. Islatravir is the first oral drug in phase three development for HIV prevention and treatment.
At the ongoing virtual session of the HIV research for prevention conference, scientists expressed optimism that the drug will appeal to persons at risk of the virus.
“COVID-19 has disrupted research around the world, so it’s especially exciting to see this new progress,” President of the International Aid Society, Adeeba Kamarulzaman said. She added that “These research advances on options like broadly neutralizing antibodies and injectable PrEP could help significantly strengthen our HIV prevention toolkit.”
South-africa
Japan
Tokyo
South-african
Adeeba-kamarulzaman
Phuong-nguyen
Sinead-delany-moretlwe
Luke-international
International-aid-society
Saharan-africa
ஜப்பான்
டோக்கியோ
vimarsana © 2020. All Rights Reserved.